Log in
NASDAQ:LMNX

Luminex Stock Forecast, Price & News

$25.28
+0.52 (+2.10 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$24.52
Now: $25.28
$25.58
50-Day Range
$24.03
MA: $29.50
$40.50
52-Week Range
$17.34
Now: $25.28
$41.69
Volume850,948 shs
Average Volume667,157 shs
Market Capitalization$1.17 billion
P/E Ratio109.92
Dividend Yield1.45%
Beta0.58
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Read More
Luminex logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.0Dividend Strength: 0.8Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LMNX
CUSIP55027E10
Phone512-219-8020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$334.64 million
Cash Flow$0.43 per share
Book Value$10.32 per share

Profitability

Net Income$-3,840,000.00

Miscellaneous

Employees1,247
Market Cap$1.17 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$25.28
+0.52 (+2.10 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Luminex (NASDAQ:LMNX) Frequently Asked Questions

How has Luminex's stock been impacted by COVID-19 (Coronavirus)?

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LMNX stock has decreased by 6.8% and is now trading at $25.28.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Luminex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Luminex
.

When is Luminex's next earnings date?

Luminex is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Luminex
.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) posted its quarterly earnings results on Tuesday, August, 4th. The medical instruments supplier reported $0.27 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.08 by $0.19. The medical instruments supplier earned $109.52 million during the quarter, compared to analyst estimates of $107.33 million. Luminex had a return on equity of 2.38% and a net margin of 3.04%. The business's quarterly revenue was up 31.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.11) EPS.
View Luminex's earnings history
.

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex declared a quarterly dividend on Wednesday, September 16th. Shareholders of record on Thursday, September 24th will be given a dividend of $0.09 per share on Thursday, October 15th. This represents a $0.36 annualized dividend and a dividend yield of 1.42%. The ex-dividend date of this dividend is Wednesday, September 23rd.
View Luminex's dividend history
.

What guidance has Luminex issued on next quarter's earnings?

Luminex updated its third quarter 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $100 million, compared to the consensus revenue estimate of $89.47 million.

What price target have analysts set for LMNX?

3 analysts have issued 12 month price targets for Luminex's stock. Their forecasts range from $21.00 to $38.00. On average, they anticipate Luminex's stock price to reach $30.33 in the next twelve months. This suggests a possible upside of 20.0% from the stock's current price.
View analysts' price targets for Luminex
.

Who are some of Luminex's key competitors?

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include NVIDIA (NVDA), Baidu (BIDU), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Square (SQ), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Micron Technology (MU), AbbVie (ABBV) and Inseego (INSG).

Who are Luminex's key executives?

Luminex's management team includes the following people:
  • Mr. Nachum Shamir, CEO, Pres & Director (Age 65)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 57)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 49)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 57)

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Who are Luminex's major shareholders?

Luminex's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.15%), Goldman Sachs Group Inc. (3.43%), Neuberger Berman Group LLC (2.13%), Copeland Capital Management LLC (1.83%), Balyasny Asset Management LLC (1.75%) and Bank of America Corp DE (1.53%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers and Richard W Rew II.
View institutional ownership trends for Luminex
.

Which major investors are selling Luminex stock?

LMNX stock was sold by a variety of institutional investors in the last quarter, including Glenmede Trust Co. NA, Neuberger Berman Group LLC, Bank of Montreal Can, Great Lakes Advisors LLC, Cowen Prime Services LLC, AQR Capital Management LLC, Bank of New York Mellon Corp, and Prudential Financial Inc.. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers, and Richard W Rew II.
View insider buying and selling activity for Luminex
.

Which major investors are buying Luminex stock?

LMNX stock was acquired by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Copeland Capital Management LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Vanguard Group Inc., Grantham Mayo Van Otterloo & Co. LLC, Intrinsic Edge Capital Management LLC, and Man Group plc. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, and Nachum Shamir.
View insider buying and selling activity for Luminex
.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $25.28.

How big of a company is Luminex?

Luminex has a market capitalization of $1.17 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 1,247 workers across the globe.

What is Luminex's official website?

The official website for Luminex is www.luminexcorp.com.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.